

## S.F. No. 2888 – Prescription Monitoring Program Modifications

**Author:** Senator Melissa H. Wiklund

**Prepared by:** Alexis C. Stangl, Director (651/296-4397)

**Date:** March 20, 2023

---

**Section 1 [Reporting requirements; notice]** provides that a dispenser is not required to submit data to the prescription electronic reporting system on prescriptions dispensed for individuals whose prescriptions are being sent from Minnesota to another state if the data is reported to the prescription drug monitoring program in the state where it is received. Allows a dispenser to provide the notice of the reporting requirements to a patient’s authorized representative. Requires a dispenser to submit the required information in a timely manner. If no reportable prescriptions are dispensed on a day, the dispenser must submit a report to that effect. A dispenser must submit accurate information to the system and must correct any errors within seven calendar days.

**Section 2 [Use of data by board]** makes clarifying changes. Specifies that data reported for prescriptions dispensed on or after January 1, 2020, must be destroyed no later than 12 months from the date the prescription was reported.

**Section 3 [Access to reporting system data]** makes modifications to who may access data in the reporting system. A licensed dispensing practitioner or licensed pharmacist may access the reporting system data to determine whether corrections made are accurate. Amends the provision related to authorized personnel of a vendor to refer to authorized personnel under contract with the board or the state who are approved by the board to access the data. Allows contract personnel to access the data for evaluation of the program. Separates the Board of Pharmacy into its own clause and allows the board personnel to access data to conduct an investigation of a specific licensee or registrant. The board may also obtain utilization data. Updates cross references.

**Section 4 [Immunity from liability]** amends the immunity provisions. Strikes the language regarding a pharmacist or prescriber not seeking or obtaining information from the program. Specifies that the immunity from liability does not extend to the requirements to access the data on patients receiving an opiate.

**Section 5 [Appropriation]** appropriates \$753,000 in fiscal year 2024 from the general fund to the Board of Pharmacy for the prescription monitoring program. This is a onetime appropriation and is available until June 30, 2025.